Currently the Enterprise Value (EV) is not available for Alnylam Pharmaceuticals.
n/a
n/a
n/a
n/a
Financial Position
The company has a current ratio of 2.78,
with a Debt / Equity ratio of 19.32.
2.78
2.71
19.32
-7.25
-30.43
-1.25
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
n/a
n/a
n/a
$1.01M
$-124.73K
2,230
0.53
4.12
Taxes
-99.22M
26.29%
Stock Price Statistics
The stock price has increased by 80.35% in the
last 52 weeks. The beta is 0.25, so Alnylam Pharmaceuticals's
price volatility has been higher than the market average.
0.25
80.35%
382.12
291.38
68.02
1,050,527
Income Statement
In the last 12 months, Alnylam Pharmaceuticals had revenue of 2.25B
and earned -278.16M
in profits. Earnings per share was -2.16.